Labiotech.eu

roche morphosys antibody alzheimers gantenerumab 1

News and Trends 14 Mar 2017

Can Roche & MorphoSys beat the odds in new Alzheimer’s Phase III Trials?

After recent late-stage disappointments from Eli Lilly and Merck, Roche and Morphosys are stepping up with two new Phase III trials in Alzheimer’s. Roche just announced plans to start two new Phase III studies in Alzheimer’s with its antibody candidate gantenerumab, initially developed by the German biotech giant MorphoSys. The trials are expected to begin later this year, but Roche […]

March 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Mar 2017

The First 3D Structure of Active DNA could advance Stem Cell Therapies

Scientists from the University of Cambridge have determined the first 3D structures of mammalian genomes from individual cells. For the first time, researchers from the University of Cambridge were able to determine the 3D structure of an active mouse genome in embryonic stem cells. Tim Stevens and his colleagues used a combination of imaging and […]

March 14, 2017 - 3 minutesmins - By Melanie De Almeida

Spain biotech ecosystem Joan Perello Sanifit Joel Jean Mairet Ysios Luis Mora PharmaMar

Interview 14 Mar 2017

Spain’s Biotech Ecosystem is Starting to Rise! Meet the Revolution’s Leaders

I interviewed three of the leaders of Spain’s biotech ecosystem: they all agree that the country is at an inflection point for growth and international recognition. This all started when I realized there’s usually far less biotech news coming our way from my home country, Spain, than from the UK, France or Germany. I decided to […]

March 14, 2017 - 8 minutesmins - By Clara Rodríguez Fernández

Interview 13 Mar 2017

Infographic: The Microbiome Market & Research by the Numbers

A new infographic from Intellisness describes global therapeutic efforts in the microbiome through target indications, investment and patents. Image from freedomnaruk / shutterstock.com

March 13, 2017 - 1 minutemin - By Evelyn Warner

Tigenix AlloCSC 01 stem cell therapy AMI

News and Trends 13 Mar 2017

New Cardiac Stem Cell Therapy passes Phase I/II Trials

TiGenix announces positive one-year results for its phase I/II trial of donor-derived cardiac stem cell therapy in acute myocardial infarction (AMI). The Belgian biotech TiGenix is developing allogeneic stem cell therapies. Now the company has announced that its cardiac stem cell therapy AlloCSC-01 reached its primary endpoints in a phase I/II trial. In 2015, the company acquired Coretherapix in a €292M deal for its allogeneic cardiac stem […]

March 13, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 13 Mar 2017

This Dutch Company is Upgrading ADCs for Immunotherapy

T-Guard is CEO and co-founder Ypke van Oosterhout’s life work. He told us about the technology that he has been developing since his graduate studies. It was during his post-MSc research that Ypke van Oosterhout ‘discovered’ T-Guard, a technology which neutralizes rogue T cells. Seeing its clinical potential, Oosterhout took the concept and ran with it — […]

March 13, 2017 - 7 minutesmins - By External Contributor

Interview 13 Mar 2017

Meet the Omics Entrepreneur who also Co-Founded EMBL

If you haven’t heard of Kai Simons, his mile-long list of accomplishments will make you wonder why. He told us some of what he learned along the way. Our Head of Business Development, Tom, was on the train from Paris to Lille for an intense day of sales meetings when he pulled up the bio […]

March 13, 2017 - 7 minutesmins - By Evelyn Warner

News and Trends 11 Mar 2017

You Can Watch Fleming’s Original Penicillin Culture in Oxford!

The Museum of the History of Science in Oxford is hosting an exhibition on the history of penicillin and the current challenges of antibiotic resistance featuring the first culture used to extract the antibiotic. The discovery of penicillin by Alexander Fleming in the early 20th century changed the world of medicine. Antibiotics have saved millions […]

March 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Mar 2017

Galapagos finds a Partner to Boost its Pipeline with Drug Combinations

Galapagos and Pharnext will work together to develop low-dose drug combinations that improve drug efficacy and target new indications. Galapagos, the biggest biotech in Belgium, has closed an R&D agreement with the French Pharnext to develop drug combinations of the billion-euro biotech’s drug candidates with already approved drugs. While Pharnext’s focus has been neurodegenerative diseases, the […]

March 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Mar 2017

SynBio Success with Enzyme opens Jet Fuel Production Possibilities

The well-known but stubborn FAS enzyme has been successfully modified to make petrol and jet fuel. This research opens up possibilities to produce biofuels with engineered microorganisms, or “cell factories”. Researchers from Chalmers University of Technology in Sweden have developed a method to modify the enzyme fatty acid synthase (FAS). This complex enzyme has long been […]

March 10, 2017 - 2 minutesmins - By Denise Neves Gameiro

Research Integrin beta 3 cellular senescence

More News! 9 Mar 2017

There’s a New Target for Anti-Aging Therapies

According to a study at Queen Mary University of London (QMUL) published in the journal Cell Reports, the protein integrin-ß3 is a new marker and regulator of cellular senescence. Past research has revealed that the rising number of senescent cells, which appear during normal ageing, contributes to many age-related diseases. In a new study by Ana O’Loghlen and collegues, integrin-ß3 has been identified as […]

March 9, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 9 Mar 2017

Even if you don’t like IP, here’s Why Biotech Should Care about It

Biotech is renowned for its huge profits; but these would be nonexistent without intellectual property. What is the role of IP law in the industry? There is yet no other industry sector in which IP plays such an important role as in biotech, life sciences and pharma. The development of a new drug is a costly matter […]

March 9, 2017 - 4 minutesmins - By External Contributor

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Can Roche & MorphoSys beat the odds in new Alzheimer’s Phase III Trials?

The First 3D Structure of Active DNA could advance Stem Cell Therapies

Spain’s Biotech Ecosystem is Starting to Rise! Meet the Revolution’s Leaders

Infographic: The Microbiome Market & Research by the Numbers

New Cardiac Stem Cell Therapy passes Phase I/II Trials

This Dutch Company is Upgrading ADCs for Immunotherapy

Meet the Omics Entrepreneur who also Co-Founded EMBL

You Can Watch Fleming’s Original Penicillin Culture in Oxford!

Galapagos finds a Partner to Boost its Pipeline with Drug Combinations

SynBio Success with Enzyme opens Jet Fuel Production Possibilities

There’s a New Target for Anti-Aging Therapies

Even if you don’t like IP, here’s Why Biotech Should Care about It

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!